Literature DB >> 24451040

The economic impact of acute coronary syndrome on length of stay: an analysis using the Healthcare Cost and Utilization Project (HCUP) databases.

Joyce C LaMori1, Omar Shoheiber, Kellie Dudash, Concetta Crivera, Samir H Mody.   

Abstract

OBJECTIVE: To assess the economic impact of initial and repeat hospitalizations associated with acute coronary syndrome (ACS) over 1 year (2009). DESIGN AND METHODS: National- and state-level data on length of stay (LOS) and related charges for ACS-associated hospital admissions were assessed using two Healthcare Utilization Project databases. The first, the Nationwide Inpatient Sample (NIS), provided clinical and resource use information from ∼8 million hospital stays, representing a 20% stratified sample of ∼40 million annual hospital stays in the US in 2009. The second, the State Inpatient Databases, provided 100% of inpatient data from nine states that included both patient age and linked information on multiple patient admissions within the same calendar year. For patients with repeat admissions, the LOS, primary diagnosis, and total charges between the first and subsequent admissions were evaluated. All patients≥18 years of age with at least one diagnosis of ACS, defined using the International Classification of Diseases, 9th Revision, were included (code 410.xx [except 410.x2], 411.1x and 411.8x). Variables evaluated for each discharge included demographics, cardiovascular events and procedures, LOS, discharge status, and total charges.
RESULTS: The NIS reported 1,437,735 discharges for ACS in 2009. In this dataset, mean LOS for an initial ACS event was 5.56 days. Patients>65 years of age had the highest numbers of admissions; this group also had the most comorbidities. Approximately 40% of ACS patients with data on repeat visits had more than one admission, >70% of these within 2 months of the primary discharge. Mean charges were $71,336 for the first admission and $53,290 for the second admission.
CONCLUSION: Despite a variety of new therapies to prevent ACS, it remains a common condition. Better therapies are called for if the clinical and cost burden of ACS is to be alleviated.

Entities:  

Mesh:

Year:  2014        PMID: 24451040     DOI: 10.3111/13696998.2014.885907

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  6 in total

1.  Health System Affiliation and 30-Day Readmission After Heart Attack in Black Men.

Authors:  Jessica H Williams; Stephanie Jarosek; Nathan Carroll; Yunhua Fan; Allyson G Hall
Journal:  Am J Prev Med       Date:  2018-11       Impact factor: 5.043

2.  Temporary Mechanical Circulatory Support for Refractory Cardiogenic Shock Before Left Ventricular Assist Device Surgery.

Authors:  Saraschandra Vallabhajosyula; Shilpkumar Arora; Sopan Lahewala; Varun Kumar; Ghanshyam P S Shantha; Jacob C Jentzer; John M Stulak; Bernard J Gersh; Rajiv Gulati; Charanjit S Rihal; Abhiram Prasad; Abhishek J Deshmukh
Journal:  J Am Heart Assoc       Date:  2018-11-20       Impact factor: 5.501

3.  Treatment Outcomes of Patients with Acute Coronary Syndrome Admitted to Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.

Authors:  Kassahun Bogale; Desalew Mekonnen; Teshome Nedi; Minyahil Alebachew Woldu
Journal:  Clin Med Insights Cardiol       Date:  2019-04-17

4.  Pressure Relieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2): Clinical and Health Economic Results of a Randomised Controlled Trial.

Authors:  Jane Nixon; Isabelle L Smith; Sarah Brown; Elizabeth McGinnis; Armando Vargas-Palacios; E Andrea Nelson; Susanne Coleman; Howard Collier; Catherine Fernandez; Rachael Gilberts; Valerie Henderson; Delia Muir; Nikki Stubbs; Kay Walker; Lyn Wilson; Claire Hulme
Journal:  EClinicalMedicine       Date:  2019-09-03

5.  Intracoronary Injection of Autologous CD34+ Cells Improves One-Year Left Ventricular Systolic Function in Patients with Diffuse Coronary Artery Disease and Preserved Cardiac Performance-A Randomized, Open-Label, Controlled Phase II Clinical Trial.

Authors:  Pei-Hsun Sung; Yi-Chen Li; Mel S Lee; Hao-Yi Hsiao; Ming-Chun Ma; Sung-Nan Pei; Hsin-Ju Chiang; Fan-Yen Lee; Hon-Kan Yip
Journal:  J Clin Med       Date:  2020-04-07       Impact factor: 4.241

6.  Thirty-day hospital revisits after prostate brachytherapy: who is at risk?

Authors:  Belinda Li; Eric J Kirshenbaum; Robert H Blackwell; William S Gange; Jennifer Saluk; Matthew A C Zapf; Anai N Kothari; Robert C Flanigan; Gopal N Gupta
Journal:  Prostate Int       Date:  2018-03-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.